1
On Wednesday, Zymeworks Inc. (NASDAQ:ZYME) released fourth-quarter financial results. The company reported an earnings loss of 31 cents per share, missing the consensus loss of 3 cents.
Sales came at $31.03 million, missing the consensus of $45.2 million.
In its fourth-quarter earnings results, Zymeworks said it is increasing its development efforts on plans for ZW251.
“Based on our encouraging preclinical results and the unique potential opportunity to help hepatocellular carcinoma patients, we have decided to reprioritize resources for the advancement of ZW251, for which an IND submission is now planned for mid-2025,” Zymeworks said in a statement.
“As a result, …
